---
title: "Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293962004.md"
description: "LifeSci Capital analyst Charles Zhu maintains a Buy rating on Kura Oncology with a $28 price target, citing encouraging darlifarnib combination data in renal cell carcinoma. He highlights favorable progression-free survival and manageable safety profiles. H.C. Wainwright also reiterated a Buy rating with a $40 target."
datetime: "2026-07-27T17:45:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293962004.md)
  - [en](https://longbridge.com/en/news/293962004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293962004.md)
---

# Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data

LifeSci Capital analyst Charles Zhu has maintained their bullish stance on KURA stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Charles Zhu has given his Buy rating due to a combination of factors that highlight both clinical promise and a favorable risk‑reward setup for Kura Oncology. He views the updated darlifarnib plus cabozantinib data in cabozantinib‑naive clear cell renal cell carcinoma as meaningfully encouraging, with confirmed response rates in the mid‑30% range that sit at the upper end of historical cabozantinib benchmarks.

Zhu also emphasizes that the median progression‑free survival of 13 months compares well against key cabozantinib monotherapy and combination studies, suggesting potential differentiation despite some investor concerns around overall response rate versus legacy regimens. Safety appears manageable and consistent with prior darlifarnib experience, and when combined with Kura’s roughly two years of cash runway and current valuation, he believes the stock offers attractive upside, supporting his unchanged $28 price target and Buy recommendation.

Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Kura Oncology, and Immunome. According to TipRanks, Zhu has an average return of 23.4% and a 59.73% success rate on recommended stocks.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [IMNM.US](https://longbridge.com/en/quote/IMNM.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial](https://longbridge.com/en/news/293917050.md)
- [Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma](https://longbridge.com/en/news/293940059.md)
- [Kura Oncology Reports 50% Response Rate in RCC Combination Study](https://longbridge.com/en/news/293955319.md)
- [Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)](https://longbridge.com/en/news/293454564.md)
- [Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement](https://longbridge.com/en/news/294265229.md)